Search Results
Your search for all items matches 34717 pages
Showing 13551 - 13600Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies
A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies. This agent is designed to overcome several challenges inherent in CAR T-cell therapy, including CD19-antigen escape, which leads to relapse in ...
Step Counts May Help Predict Treatment Outcomes for Patients With NSCLC
A new study suggests step counters could play a role in predicting outcomes for people undergoing chemoradiation therapy for lung cancer. These findings were published by Ohri et al in the International Journal of Radiation Oncology • Biology • Physics. “I consider step counts to be a new vital...
Prevalence of Alcohol Use Among Patients With Cancer and Survivors
New research published by Nina N. Sanford, MD, and colleagues in JNCCN—Journal of the National Comprehensive Cancer Network has found most cancer survivors reported that they are current alcohol drinkers, with a subset of those survivors self-reporting excessive drinking behaviors. “We recommend...
Dietary Supplement Use During Adjuvant Chemotherapy and Treatment Outcomes in Patients With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Ambrosone et al, an analysis of the SWOG S0221 trial population suggests that use of antioxidant and nonantioxidant dietary supplements, but not multivitamins, before and during adjuvant chemotherapy may be associated with poorer treatment outcomes ...
Addition of Olaparib to Bevacizumab Maintenance in Patients With Advanced Ovarian Cancer Responding to First-Line Therapy
As reported in The New England Journal of Medicine by Isabelle Ray-Coquard, MD, PhD, and colleagues, the phase III PAOLA-1 trial has shown a progression-free survival benefit with the addition of olaparib to bevacizumab maintenance in patients with advanced ovarian cancer responding to first-line...
Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial
As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...
FDA Approves PD-1 Inhibitor for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have...
Many Pelvic Examinations and Papanicolaou Tests Performed on Young Women May Be Unnecessary
Pelvic examinations and cervical cancer screenings are no longer recommended for most females under age 21 during routine health visits, but a new study has found that millions of young women are undergoing the tests, which can lead to false-positive testing, overtreatment, anxiety, and needless...
Does Weight-Loss Surgery Lower the Risk of Malignant Melanoma?
Bariatric surgery is associated with a distinct reduction in skin cancer risk, according to findings published by Taube et al in JAMA Dermatology. This finding further substantiates the connection between weight loss and malignant skin cancer. “This [study] provides further evidence for a...
Largest Single-Year Drop in Cancer Mortality Reported in ‘Cancer Statistics, 2020’
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
Recurrence Risk With Accelerated Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Early Breast Cancer: Long-Term Follow-up
As reported in The Lancet by Frank A. Vicini, MD, and colleagues, 10-year follow-up in the phase III NSABP B-39/RTOG 0413 equivalence trial has shown that accelerated partial-breast irradiation did not achieve equivalence to whole-breast irradiation in preventing local recurrence in women receiving ...
Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens. Study...
T-DM1 Shows Activity in HER2-Amplified Salivary Gland Cancer in Small Patient Sample of NCI-MATCH
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) showed activity in HER2-amplified salivary gland tumors, according to data published by Jhaveri et al in Annals of Oncology. The publication is for ‘Arm Q,’ which is one of nearly 40 single-arm phase II treatments in the NCI-Molecular...
Physical Activity at Recommended Levels May Lower Risk of Multiple Cancers
A pooled analysis of nine prospective studies involving more than 750,000 adults has found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a dose/response relationship. These findings were published by...
Is Pembrolizumab Active in Pediatric Patients With PD-L1–Positive Advanced Solid Tumors or Lymphoma?
Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was...
FDA Pooled Analysis of CDK4/6 Inhibitor Treatment for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the magnitude of progression-free survival benefit with the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy in women with...
Long-Term Results of Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab in Patients With Stage III NSCLC
As reported in the Journal of Clinical Oncology by Jeffrey D. Bradley, MD, and colleagues, long-term results of the phase III NRG Oncology/RTOG 0617 trial indicate that standard-dose radiotherapy should remain the standard of care in chemoradiotherapy for nonresectable stage III non–small cell...
One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer
Testicular cancer recurrence may be prevented by giving men one cycle of chemotherapy instead of the two cycles used as standard. Lowering the overall exposure to chemotherapy also reduced side effects. These findings were published by Cullen et al in European Urology. Testicular cancer is the most ...
Pembrolizumab in KRAS-Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC
In an analysis reported in Annals of Oncology, Roy S. Herbst, MD, PhD, and colleagues found that pembrolizumab was active in both KRAS-mutant and wild-type tumors in a subgroup of patients in the KEYNOTE-042 trial with programmed cell death ligand 1 (PD-L1)-positive nonsquamous non–small cell lung...
JAVELIN Bladder 100 Study of Avelumab for Urothelial Cancer Meets Primary Endpoint
The phase III JAVELIN Bladder 100 trial met its primary endpoint of overall survival at the planned interim analysis. In this study, patients with previously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy and who were randomly...
Neoadjuvant vs Concurrent ADT With Dose-Escalated Radiotherapy for Localized Prostate Cancer
In a two-institute phase III trial reported in the Journal of Clinical Oncology, Malone et al found no difference in biochemical relapse–free survival with androgen-deprivation therapy (ADT) initiated prior to or concurrently with dose-escalated external-beam radiotherapy in patients with localized ...
Rates of Guideline-Aligned Genomic Profiling in Patients Diagnosed With Metastatic Colon Cancer
In a study reported in JCO Precision Oncology, Gutierrez et al found that most patients in a U.S. sample diagnosed with metastatic colon cancer between 2013 and 2017 did not receive guideline-aligned genomic testing for RAS, BRAF, and microsatellite instability/mismatch repair–deficiency (MSI/dMMR) ...
Overall Survival With the Addition of Ribociclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: MONALEESA-3
As reported in The New England Journal of Medicine by Dennis J. Slamon, MD, PhD, and colleagues, in the phase III MONALEESA-3 trial, the second interim analysis of overall survival has shown a significant benefit with the addition of ribociclib to fulvestrant in first- or second-line treatment of...
Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
As reported in The Lancet by Maria-Victoria Mateos, MD, and colleagues, interim analysis of overall survival in the phase III ALCYONE trial has shown a significant benefit of the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in patients with newly diagnosed multiple...
Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention
As reported by Jack Cuzick, PhD, and colleagues in The Lancet, blinded follow-up of the IBIS-II trial has shown the continued benefit of anastrozole vs placebo in preventing breast cancer in high-risk postmenopausal women during the 5-year posttreatment period. For the international double-blind...
Cardiovascular Risks After Bleomycin/Etoposide/Cisplatin Treatment for Germ Cell Cancer
In a Danish study reported in the Journal of Clinical Oncology, Lauritsen et al found that patients treated for germ cell cancer exhibited an increase of cardiovascular risk factors and cardiovascular disease at short- and long-term follow-up. Study Details The study involved 5,185 patients with...
Saliva Test May Play A Role in the Early Detection of HPV-Related Oropharyngeal Cancer
A report by Wang et al in The Journal of Molecular Diagnostics described the use of acoustofluidics, a noninvasive method that analyzes saliva for the presence of human papillomavirus type 16 (HPV-16), the pathogenic strain of the disease associated with oropharyngeal cancers. This novel technique...
FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes
Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration (FDA) has issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products that appeal to children, including fruit...
Osimertinib in Patients With NSCLC Harboring Uncommon EGFR Mutations
In a Korean phase II study reported in the Journal of Clinical Oncology, Myung-Ju Ahn, MD, PhD, and colleagues found that osimertinib was active in patients with metastatic or recurrent non–small cell lung cancer (NSCLC) with uncommon EGFR mutations. Study Details In the multicenter study, 36...
D-CARE Trial: Adjuvant Denosumab for Patients With Early Breast Cancer
As reported in The Lancet Oncology by Robert Coleman, MD, FRCP, and colleagues, the phase III D-CARE trial has shown no benefit of adjuvant therapy with the RANKL inhibitor denosumab vs placebo in improving bone metastasis–free survival in women with moderate- to high-risk early breast cancer....
Asciminib for Patients With CML After Failure of ABL Kinase Inhibitor Treatment
In a phase I trial reported in The New England Journal of Medicine, Hughes et al found that asciminib, an oral BCR-ABL1 inhibitor with a mechanism of action different from available ABL1 tyrosine kinase inhibitors, was active in patients with chronic myeloid leukemia (CML) after failure of ABL...
Screening Rates Rose Among People Aged 45–49 After Release of Updated Colorectal Cancer Guidelines
Colorectal cancer screening rates more than doubled among people aged 45 to 49 in the months after the release of updated American Cancer Society guidelines in 2018 recommending screening in that age group, according to a new study. According to the findings from Fedewa et al—published in...
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
On December 27, 2019, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma as detected by an FDA-approved test whose disease has not ...
Your Stories Podcast to Return in 2020 With New Episodes
A new season of Your Stories, the popular podcast series from Conquer Cancer®, the ASCO Foundation, will premiere in 2020. New episodes will be released bimonthly and will feature candid conversations among doctors, patients, caregivers, and research pioneers on their experiences conquering...
Help Patients Learn How to Manage Pain Effectively
Nearly all cancer-related pain can be successfully managed. Give your patients the ASCO Answers Managing Cancer-Related Pain booklet, which explains the importance of pain relief, including its causes; how it is diagnosed; types of pain relief strategies; and a tracking sheet to help patients...
Final Answers
Emily Johnston, MD, MS, thinks about death a lot. “I wish we would stop saying people ‘lost a battle’ with cancer when someone dies,” she said. Dr. Johnston specializes in pediatric oncology at Children’s of Alabama hospital. Conquering cancer, she believes, doesn’t simply mean surviving it—it...
Preliminary Study Finds ASCO Decision Aid May Improve Quality of Serious Adverse Events Reporting
Sponsors of clinical trials conducted under investigational new drug (IND) applications are required by the U.S. Food and Drug Administration (FDA) to report serious adverse events that are unexpected and suspected to be related to the drug. However, contrary to FDA guidance, investigators often...
Make a Holiday Gift to Conquer Cancer,® the ASCO Foundation
Help fund breakthrough cancer research on behalf of someone you love this holiday season. Make a gift in honor or in memory of a loved one, and then send an e-card or mailed notification of your tribute. For many families, this time of year is marked by worry or grief rather than joy. With your...
Highlights From the 2019 ASCO Research Community Forum Annual Meeting
Researchers from around the country joined together for learning and collaboration at the 2019 ASCO Research Community Forum (RCF) Annual Meeting in September. During the meeting, Aisha Peterson Johnson, MD, MPH, MBA, of the U.S. Food and Drug Administration (FDA) Office of Compliance, delivered a...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer®, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, funded 21 Young Investigator...
CMS Finalizes Updates to E&M Codes, Establishes MIPS Value Pathways
The Centers for Medicare & Medicaid Services (CMS) released its final rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B reimbursement policies, including proposals related to the Quality Payment Program (QPP). The estimated impact of the final MPFS...
ASCO and IASLC Collaborate to Improve the Quality of Lung Cancer Care in Brazil
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer. Lung cancer is one of the most prevalent and deadly types of cancer in Brazil.1 Providing a platform for health-care providers to...
Trastuzumab and Hyaluronidase-oysk for Subcutaneous Use in HER2-Positive Breast Cancer
Early in 2019, trastuzumab and the endoglycosidase hyaluronidase-oysk for subcutaneous injection was approved in the treatment of HER2-positive breast cancer.1,2 The agent is indicated for adjuvant treatment of patients with HER2-overexpressing node-positive or node-negative (estrogen...
V. Craig Jordan, PhD, DSc, Receives Award at Buckingham Palace
V. Craig Jordan, CMG, OBE, PhD, DSc, was presented with his Companion of the Most Distinguished Order of Saint Michael and Saint George (CMG) for services to women’s health. Prince William presented the award on November 5. Dr. Jordan was recognized for his discovery and development of selective...
Rituximab-abbs: Biosimilar to Rituximab for Non-Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Late in 2018, rituximab-abbs was approved as the first...
Taking a Reasonable Approach to Treating Newly Diagnosed Multiple Myeloma
Multiple myeloma is a malignancy characterized by clonal proliferation of terminally differentiated plasma cells within the bone marrow. Although it leads to a host of different issues within the body, overall survival has steadily improved in recent years. “This is largely because of better...
KEYNOTE-013 and KEYNOTE-170: Improving the Precision of Checkpoint Blockade in Patients With Diffuse Large B-Cell Lymphoma
Primary mediastinal B-cell lymphoma is an uncommon but distinct clinicopathologic variant of diffuse large B-cell lymphoma (DLBCL) that typically presents with an aggressive mediastinal mass and invasion of local structures. Most patients are young, typically in their 20s and 30s, and there is a...
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: KEYNOTE-013 and KEYNOTE-170
Findings in the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials, reported in the Journal of Clinical Oncology by Philippe Armand, MD, PhD, of DanaFarber Cancer Institute, and colleagues, indicate that pembrolizumab is active in relapsed or refractory primary mediastinal large B-cell...
Oncology Analytics Appoints Lee Newcomer, MD, as Strategic Advisor
Oncology Analytics, a technology-enabled service company that provides health plans, providers, and patients with an evidence-based, analytics-focused approach to utilization management, purpose-built for oncology, has announced the appointment of Lee Newcomer, MD, as a strategic advisor. Dr....
New Award and Grant to Support Pediatric Cancer Research
The American Association for Cancer Research (AACR) and the St. Baldrick’s Foundation announced the creation of the AACR–St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research. The award includes a grant to provide support for a junior faculty investigator to...
